Pretreatment platelet count is a prognostic marker in lung cancer
Based on data from 7,908 lung cancer patients, a recent study shows that both low and high platelet counts are adverse prognostic factors in NSCLC. In low count showed an 75% increased risk of death and 24% in high count. In SCLC, low count is an even stronger marker with a 271% increased risk of death.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.